PMID- 24531612
OWN - NLM
STAT- MEDLINE
DCOM- 20140918
LR  - 20140526
IS  - 1432-0843 (Electronic)
IS  - 0344-5704 (Linking)
VI  - 73
IP  - 6
DP  - 2014 Jun
TI  - Recommendations from the Spanish Oncology Genitourinary Group for the treatment 
      of patients with renal cell carcinoma.
PG  - 1095-107
LID - 10.1007/s00280-014-2413-0 [doi]
AB  - Clear-cell renal cell carcinoma (RCC) is the most common kidney cancer. New 
      treatment options of localized RCC recently incorporated include laparoscopic 
      surgery, nephron-sparing surgery, ablative techniques and active surveillance. 
      But 50 % of patients may develop disease recurrence attributable to subclinical 
      metastases. In these cases, and considering the low benefits of chemotherapy, new 
      targeted therapies such as tyrosine kinase inhibitors (TKIs) and mammalian target 
      of rapamycin (mTOR) inhibitors have been developed as first- and second-line 
      treatment. Both sunitinib and pazopanib are TKIs that constitute the first-line 
      treatment option in patients with metastatic RCC. As second-line treatment, 
      sequential therapy with a second TKI or a mTOR inhibitor is recommended. This 
      review has collected together a series of recommendations issued by the Spanish 
      Oncology Genitourinary Group with the aim of facilitating the treatment of these 
      patients. Each recommendation is accompanied by the level of evidence and grade 
      of recommendation on the basis of the available data.
FAU - Garcia Del Muro, Xavier
AU  - Garcia Del Muro X
AD  - Genitourinary and Sarcoma Unit, Department of Medical Oncology, Institut Catala 
      d'Oncologia L'Hospitalet, Gran Via de L'Hospitalet, 199-203, 08908, L'Hospitalet, 
      Barcelona, Spain, garciadelmuro@iconcologia.net.
FAU - Gallardo, Enrique
AU  - Gallardo E
FAU - Garcia Carbonero, Iciar
AU  - Garcia Carbonero I
FAU - Lainez, Nuria
AU  - Lainez N
FAU - Jose Mendez, Maria
AU  - Jose Mendez M
FAU - Maroto, Pablo
AU  - Maroto P
FAU - Ochoa de Olza, Maria
AU  - Ochoa de Olza M
FAU - Puente, Javier
AU  - Puente J
FAU - Reynes, Gaspar
AU  - Reynes G
FAU - Rubio, Jose
AU  - Rubio J
FAU - Santander, Carmen
AU  - Santander C
FAU - Suarez, Cristina
AU  - Suarez C
FAU - Vazquez Estevez, Sergio
AU  - Vazquez Estevez S
FAU - Castellano, Daniel
AU  - Castellano D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20140216
PL  - Germany
TA  - Cancer Chemother Pharmacol
JT  - Cancer chemotherapy and pharmacology
JID - 7806519
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
SB  - IM
MH  - Carcinoma, Renal Cell/drug therapy/pathology/*therapy
MH  - Humans
MH  - Kidney Neoplasms/drug therapy/pathology/*therapy
MH  - Receptor Protein-Tyrosine Kinases/antagonists & inhibitors
EDAT- 2014/02/18 06:00
MHDA- 2014/09/19 06:00
CRDT- 2014/02/18 06:00
PHST- 2013/12/03 00:00 [received]
PHST- 2014/02/07 00:00 [accepted]
PHST- 2014/02/18 06:00 [entrez]
PHST- 2014/02/18 06:00 [pubmed]
PHST- 2014/09/19 06:00 [medline]
AID - 10.1007/s00280-014-2413-0 [doi]
PST - ppublish
SO  - Cancer Chemother Pharmacol. 2014 Jun;73(6):1095-107. doi: 
      10.1007/s00280-014-2413-0. Epub 2014 Feb 16.